Shots:

• The P-III MAIA study assessing Darzalex + lenalidomide & dexamethasone (DRd) vs Rd in 737 newly diagnosed patients aged 45-90yrs. with MM ineligible for high-dose CT & ASCT
• MAIA longer-term follow-up analysis showed i.e @5yrs.- OS rate (66% vs 53%)- PFS rate (53% vs 29%)- ORR (93% vs 82%) & median time to next treatment (not reached vs 42.4 mos.)- no new safety concerns were identified
• The prespecified interim analysis after a median follow-up of 56.2mos. showed a 32% reduction in risk of death- m-OS was not reached- mPFS (not reached vs 34.4mos.) PFS benefit with 47% reduction in risk of disease progression or death

  Ref: PR Newswire | Image: Janssen